Induction in chimpanzees of antibodies inhibiting receptor-mediated cell fusion by HIV glycoprotein. NLM AIDSLINE Important note: Information in this article was accurate in 1989. The state of the art may have changed since the publication date.

Click here to return to AIDSLINE main menu
DonateNow
Print this Article


Induction in chimpanzees of antibodies inhibiting receptor-mediated cell fusion by HIV glycoprotein.

Viral Immunol. 1987-88;1(3):225-40. Unique Identifier : AIDSLINE MED/89374565
Goudsmit J; Smit L; Klaver B; Asher DM; Wolff A; Gibbs CJ Jr; Gajdusek DC; Virology Department, University of Amsterdam, The Netherlands.


Abstract: Cell fusion of HTLV-IIIB-infected EBV-transformed B cells and CD4+ T cells was inhibited by sera from eight of nine HIV infected chimpanzees. Syncytia formation was reduced by sixty percent relative to control after only 5 minutes of preincubation of the HIV infected cells with immune primate serum, indicating that these antibodies have high affinity for HIV protein on the surface of infected cells. Serum dilutions that blocked formation of syncytia irreversibly within 24 hrs also blocked expression of HIV antigens by the target CD4+ cells. Three of four animals inoculated with the LAV or HTLV-IIIB strain of HIV developed antibodies inhibiting CD4-dependent cell fusion by HIV glycoprotein (CFI-antibodies) 2-3 months after inoculation coincident with development of HIV specific IgG antibodies. Similar early CFI-antibody responses occurred in two second passage chimpanzees. In contrast, a chimpanzee infected with a third passage of LAV had a delayed CFI-antibody response, indicating that variants of HIV with divergent CFI epitopes did eventually emerge. Delayed development of CFI-antibodies (6-11 months after inoculation) relative to HIV specific IgG ELISA antibody was also seen in a chimpanzee on primary passage and a chimpanzee on second passage of HTLV-IIIB. No CFI-antibodies were detected in a chimpanzee following inoculation with human brain tissue, while antibodies to other structural proteins were recognized by immunoblotting. These results indicate that changes in CFI epitopes occur under immune pressure and that the appearance of CFI-antibodies depends on the time after infection and on the degree to which CFI epitopes of the inoculum strain diverge from those of the test strain.
Keywords: Animal Antibodies, Monoclonal Antibody Formation Antigens, Differentiation, T-Lymphocyte/IMMUNOLOGY *Cell Fusion Cell Line Chimpansee troglodytes/*IMMUNOLOGY Electrophoresis, Polyacrylamide Gel Enzyme-Linked Immunosorbent Assay HIV Antigens/*IMMUNOLOGY Immunization Immunoblotting Viral Fusion Proteins/*IMMUNOLOGY JOURNAL ARTICLEKWDanimalantibodies,monoclonalantibodyformationantigens,differentiation,t-lymphocyte/immunologyKWDcellfusioncelllinechimpanseetroglodytes/KWDimmunologyelectrophoresis,polyacrylamidegelenzyme-linkedimmunosorbentassayhivantigens/KWDimmunologyimmunizationimmunoblottingviralfusionproteins/KWDimmunologyjournalarticle
891230
M89C0808

Copyright © 1989 - National Library of Medicine. Reproduced under license with the National Library of Medicine, Bethesda, MD.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1989. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1989. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .